OncoC4 is a privately-held, clinical-stage biopharmaceutical company based in Rockville, MD, dedicated to the discovery and development of biopharmaceuticals for the treatment of various cancers. With a rich pipeline of best-in-class and first-in-class immunotherapy products, OncoC4 aims to target cancer evasion of adaptive and innate immunity, while also focusing on uncoupling therapeutic effects from immunotherapy-related adverse effects.
Led by a team of experienced professionals from biotech pharma and academia, OncoC4 is committed to advancing scientific discoveries into novel therapeutics that have the potential to revolutionize cancer treatment. Through their innovative approach, OncoC4 strives to address the most pressing challenges in immunotherapy and provide hope for patients battling cancer.
Generated from the website